Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized Trial Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention CREDIT
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Study Type: Treatment
Phase: III
NCTID: NCT03533582
Principal Investigator:
Keith August
Phase III Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080/MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma LEAP-002
Phase I/II clinical trial of regorafenib plus durvalumab MEDI4736 in patients with chemo refractory advanced biliary tract cancers
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 bintrafusp alfa as First-line Treatment of Biliary Tract Cancer
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose RP2D in Adults with Advanced Hepatocellular Carcinoma HCC who are not Candidates for Standard-Of-Care Therapy.
A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT06050252
Principal Investigator:
Raed Al-Rajabi
Phase III, Open-Label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy PALOMA-3.
Study Type: Treatment
Phase: III
NCTID: NCT05388669
Principal Investigator:
Jun Zhang